Wire · opportunities
Cepheid 13-Target Respiratory Panel Gets FDA Clearance
◆ Sectors
Diagnostics
◆ Geography
United States
◆ Source
◆ Verified
Fusion42 · 30 September 2026 · Fusion42 review
Danaher's subsidiary Cepheid has received FDA 510(k) clearance for its 13-target respiratory panel, enabling its diagnostic use in the US market.
This Wire brief sits within Fusion42's coverage of Diagnostics.
◆ ◆ The Wire takeaway
You have a new opportunity to integrate fast, multiplex respiratory diagnostics into care pathways as FDA clearance cuts the path for clinical adoption in the US.
◆ Coverage
1 source · 29 Sep 2026
◆ Related on Wire
◆ Topics
DiagnosticsFDA-clearancerespiratory-diagnosticsCepheidmedical-device